DP8
CervoMed Inc., a a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of th… Read more
DP8 (DP8) - Net Assets
Latest net assets as of September 2025: €26.01 Million EUR
Based on the latest financial reports, DP8 (DP8) has net assets worth €26.01 Million EUR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€30.61 Million) and total liabilities (€4.60 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €26.01 Million |
| % of Total Assets | 84.97% |
| Annual Growth Rate | 3.94% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 313.39 |
DP8 - Net Assets Trend (2021–2024)
This chart illustrates how DP8's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for DP8 (2021–2024)
The table below shows the annual net assets of DP8 from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €39.20 Million | +431.43% |
| 2023-12-31 | €7.38 Million | +122.16% |
| 2022-12-31 | €-33.29 Million | -195.34% |
| 2021-12-31 | €34.91 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to DP8's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 5927362700.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €109.93 Million | 280.43% |
| Total Equity | €39.20 Million | 100.00% |
DP8 Competitors by Market Cap
The table below lists competitors of DP8 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Beammwave AB B
ST:BEAMMW-B
|
$20.15 Million |
|
Blueone Card Inc
PINK:BCRD
|
$20.16 Million |
|
Best Agrolife Limited
NSE:BESTAGRO
|
$20.16 Million |
|
Blue Gold Limited Class A Ordinary Shares
NASDAQ:BGL
|
$20.16 Million |
|
Chia Ta World Co Ltd
TW:2033
|
$20.15 Million |
|
Carclo plc
PINK:CCEGF
|
$20.14 Million |
|
COWELL FASHION Co.Ltd
KQ:033290
|
$20.14 Million |
|
DIC Holdings Construction JSC
VN:DC4
|
$20.14 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in DP8's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 7,376,774 to 39,202,328, a change of 31,825,554 (431.4%).
- Net loss of 16,290,695 reduced equity.
- New share issuances of 46,398,606 increased equity.
- Other factors increased equity by 1,717,643.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-16.29 Million | -41.56% |
| Share Issuances | €46.40 Million | +118.36% |
| Other Changes | €1.72 Million | +4.38% |
| Total Change | €- | 431.43% |
Book Value vs Market Value Analysis
This analysis compares DP8's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.80x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.14x to 0.80x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €25.69 | €3.62 | x |
| 2022-12-31 | €-24.48 | €3.62 | x |
| 2023-12-31 | €1.30 | €3.62 | x |
| 2024-12-31 | €4.50 | €3.62 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently DP8 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -41.56%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.10x
- Recent ROE (-41.56%) is below the historical average (-35.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -69.02% | 0.00% | 0.00x | 1.08x | €-27.59 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | €-2.47 Million |
| 2023 | -29.44% | 0.00% | 0.00x | 1.35x | €-2.91 Million |
| 2024 | -41.56% | 0.00% | 0.00x | 1.10x | €-20.21 Million |
Industry Comparison
This section compares DP8's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| DP8 (DP8) | €26.01 Million | -69.02% | 0.18x | $20.15 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |